A Randomized, <scp>Placebo‐Controlled</scp> Phase <scp>III</scp> Extension Trial of the <scp>Long‐Term</scp> Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
Kenneth Kalunian(University of California, San Diego), Hussein Al‐Mossawi(AstraZeneca (United Kingdom)), Catharina Lindholm(AstraZeneca (Finland)), Micki Hultquist(AstraZeneca (Spain)), Yoshiya Tanaka(University of Occupational and Environmental Health Japan), Ihor Hupka(AstraZeneca (Poland)), Eric F. Morand(Novartis (Switzerland)), Raj Tummala(Hofstra University), Ian N Bruce(University of Manchester), Richard Furie(Hofstra University), Gabriel Abreu(AstraZeneca (Finland)), Shanti Werther(AstraZeneca (Finland)), Lijin Zhang(AstraZeneca (Poland)), Susan Manzi(Allegheny Health Network), Kevin Winthrop(Oregon Health & Science University)
Cited by 151
Related Papers
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline
|European Respiratory Journal|2020|876
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840